

InvestTech
Advanced
Solutions



AGING
ANALYTICS
AGENCY

Longevity Industry Investment Digest

Q1 2025


Longevity Industry Investment

Principles of Longevity Investment



THE LONGEVITY ECONOMY ON A GLOBAL SCALE

Longevity Economy Scale Projections by Beginning of 2025



The Longevity Economy's Scale Projections contains global healthcare spending affecting Longevity, the combined capitalisation of publicly listed Longevity companies, the capitalisation of Longevity-related insurance and reinsurance companies, banks and pension funds and privately held Longevity companies.

Not only does ageing pose one of the most acute problems of our time - it also presents one of the most promising opportunities. Financial institutions, such as investment banks, pension funds, and insurance companies can either sink or swim when hit by the oncoming Silver Tsunami. Whether they will succeed in riding the wave or end up drowning under it will depend not only on their willingness to deploy new business models adapted to population ageing and emerging industries of AgeTech, WealthTech, and Longevity Finance, but also on the quality of Longevity analytics that they use to develop such business models.

We define the Longevity Industry as a combination of ageing, advanced preventive precision biomedicine, AgeTech, relevant parts of national healthcare budgets, and the global financial industry related to such sub-industries.


GLOBAL LONGEVITY ECOSYSTEM 2025

50,000 Companies

9,000 Investors

1,000 Hubs

20 Sectors



LONGEVITY INDUSTRY: MULTI-TRILLION DOLLAR OPPORTUNITY



FINANCIAL
TIMES

“The one billion retired people globally are a multi-trillion dollar opportunity for business “

~ Dmitry Kaminskiy, [interview in the Financial Times](#)

“We expect to add 1 billion older individuals in the next three to four decades, atop the more than 700 million older people we have today “

~ *International Monetary Fund*



LONGEVITY INDUSTRY: MULTI-TRILLION DOLLAR OPPORTUNITY

The Global Longevity Market was estimated at \$28 trillion in 2025

50,000+ companies
(incl. 500 listed companies)

1,000+ R&D hubs

9,000+ investors

1,000+ financial institutions

100+ governments

160 subsectors

The Longevity market is not only limited to anti-ageing applications of life sciences. It also includes some new sectors of the financial industry, as well as government projects (national Longevity development plans); hence, its overall size potentially exceeds \$28 trillion. As the majority of full-blown Longevity startups are quickly becoming mature companies, large institutional investors are making increasingly more investments in the industry and a full-fledged Longevity infrastructure is emerging.

There are at least 500 publicly traded corporations that can be considered part of the Longevity industry.

Longevity Biomedicine, FinTech, and AgeTech industries include 50,000+ companies, 9,000+ investors, 20 sectors, and 160 subsectors.


The Longevity Financial Industry includes 1,000+ corporations, 15 sectors, and 50 subsectors.

The Longevity Governance Landscape includes national healthcare budgets and development plans of at least 100 governments.

Note: Since there is no generally accepted methodology for their estimation, the numbers presented in the scheme are approximate.

LONGEVITY AND SILVER TSUNAMI - COLLISION OF TWO OPPOSING MEGATRENDS

Two Opposed MegaTrends



Rapid progress in biomedicine has been mainly due to the advances in collection and analysis of data. The industry is poised to witness a quantum leap in the near future, particularly because of the impact made by Artificial Intelligence on biomedicine R&D and in light of the upcoming paradigm shift from treatment to prevention.

At the same time, the inevitable Silver Tsunami (demographic ageing) places a major economic burden not only on the healthcare systems of developing nations, but also on major financial institutions, including pension funds, insurance companies, asset management firms and retail/private wealth banks. It is also expected to increase costs associated with old age.

LONGEVITY INDUSTRY MARKET TIMELINE

The first approaches

- The first scalable approaches for Longevity biomedicine and biomarkers of ageing were developed and several industry players with forward-thinking executives started launching pilot collaborations and making small investments.

Criticism

- However, only few market players believed in anti-ageing technologies.
- Many pilot projects failed due to the lack of scientific validation and immaturity of the technologies, creating a lot of criticism towards the whole industry.
- Since then the race for the acquisition of the Longevity startups began.
- Testing of the technology began.

Industry development

- Capitalisation of the industry was continuously growing.
- Many bets of early investors appeared to be justified.
- Large financial institutions, as well as government agencies, started to express interest in the Longevity industry.

Transition from quantity to quality

- An important milestone in transitioning from the quantity of Longevity startups to qualitative gains – significant number of practical validations of previously conducted research appeared during this year.
- Competition for the most successful pharma AI companies increased dramatically.

Intensive competition

- Most developed Longevity startups are becoming mature companies, large institutional investors are being attracted to the industry, full-fledged Longevity infrastructure is being developed.
- Intensive cooperation of Longevity companies with corporations, banks, and governments begins.
- Competition among advanced Longevity companies booms.

2013-2015

2016-2017

2018

2019

2020-2023

Longevity Industry Investment

Overview



InvestTech
Advanced
Solutions



AGE-FRIENDLY BANKS

The worldwide population of older people growing pushes even the most conservative financial institutions to examine how to make their products more "age-friendly." Banks that are age-friendly provide effective and specialised financial products, services, and safeguards for people over the age of 65.

The proportion of older people in the population is growing, which means there are fewer and fewer working-age people. Banks and financial services will need to meet the changing demands and expectations of customers in this new era.

Banks and financial institutions should think about creating new products for the growing number of older people, who are also living longer now and thus able to absorb higher financial risks than elderly people of past generations. So, there should be new thinking about investment plans and other products designed for this new generation of elderly citizens in this new era.

Innovation can be the answer to decumulation of wealth as well. Banks should pay attention to single elderly people who tend to live alone without descendants. These types of people need different kinds of loans that are specifically designed for retired people, such as reverse mortgages. These products can provide people the support they need for long-term, secure living.

Main Components of Age-Friendly Banking

1

Protecting older adults from financial abuse and fraud

2

Customising financial products and services to older adults needs

3

Expanding affordable financial management

4

Guaranteeing access to critical income supports

5

Facilitating ageing in the community

6

Improving the accessibility of banking for those with restricted mobility or living alone in remote areas

AGE-FRIENDLY NEOBANKS VS. TRADITIONAL BANKS

Neobanks

Neobanks are digital banks without any physical branches, developed for the growing masses of tech-savvy customers that prefer to manage their money using mobile apps or other digital media

Absence of expenses related to the maintenance of the bank's branch network

High speed and simplicity & comfort

Neobanks offer higher rate for savings and checking accounts

Neobanks work without reference to the office business hours. So, they are available 24/7 all year round. For a neobank, your location does not matter

Traditional Banks

Traditional banks have physical branches and actual people at the counters

Additional costs for customer service in offices and branches


Length of making changes and taking decisions, and administration (bureaucracy)

Traditional banks offer lower rate for savings and checking accounts compared to neobanks

Traditional banks also keep up to date. Many of them provide mobile solutions with a variety of options. However, they may not be available everywhere

Neobanks are disrupting the traditional banking system by **leveraging technology** and **artificial intelligence (AI)** to offer a range of personalised services to customers. On the other hand, **traditional banks** follow an omnichannel approach i.e. having both physical (through branches and ATMs) and digital banking presence to offer a multitude of products and services.

AGE-FRIENDLY NEOBANKS: REGIONAL PROPORTION



USA having 5 Age-Friendly neobanks (**FitnessBank**, **Lively**, **SoFi**, **Agora** and **M1 Finance**) among 11 banks, is the most active country in this field, the second place belongs to **the UK** with two banks (**Longevity Card** and **Pennyworth**) and each of other countries (**Canada**, **India**, **Switzerland** and **Netherlands**) has an Age-Friendly neobank (respectively **Tangerine**, **Ocare**, **Alpien** and **Knab**).

INVESTTECH ADVANCED SOLUTIONS: ANALYTICAL REPORTS

InvestTech Advanced Solutions in cooperation with analytical subsidiaries of Deep Knowledge Group produces regular open-access reports covering emerging technologies, innovations, companies, and trends across the variety of DeepTech domains.

These reports focus on major areas of high-potential industries, maintaining ratings of market players based on their innovation potential and business activity.

The scope of analytical reports accounts for over 10 investment digests that are subject to periodic updates. The elements comprised in every report are as follows:

Industry
Trends

Investors

Investment
Rounds

R&D Trends

Venture
Capital
Ecosystem

Private
Companies

Public
Companies

M&A
Landscape

Explore the entire scope of analytical reports at:

www.invest-solutions.tech/reports

Longevity Investment Digest

This landmark report outlines major investment rounds, and relevant R&D trends, as well as illustrates the traction of the Longevity Industry and delivers a comparison of market players. The information in the digest covers key industry trends, 23,000 Longevity companies, 50 leading investors, and more than 600 Longevity-focused publicly traded corporations.



INVESTTECH ADVANCED SOLUTIONS: PROPRIETARY ANALYTICS

Some of the more in-depth research is only available to our clients and strategic partners as proprietary analytics. As a rule, this analytics covers the topics that are of great interest to parties concerned and delivers an extensive scope of information on particular topics.

Proprietary Analytics delivers practical answers to certain questions in order to optimise the short and long-term strategies of companies related to the industry. Proprietary reports are supported by our rapidly developing data mining engine and analytics dashboards.

Ready-to-use
Proprietary
Reports

Custom
Consulting
Projects

Investment
Prospects

M&A
Prospects

Strategic
Growth Ideas

Trends
Profiling

Niche
Industries
Overviews

Case Studies

Access our website to learn more:

www.invest-solutions.tech

Proprietary Version of Longevity Derivatives and Financial Instruments Report

This report thoughtfully explores Longevity-derived financial instruments. The study includes derivatives explanation and analysis, including the comparison to other financial instruments. The proprietary version delivers an exhaustive overview of the biomarkers-based Longevity assessment solutions.



LONGEVITY FINANCE BIG DATA ANALYTICS DASHBOARD

Developed by InvestTech Advanced Solutions based on the data provided by the Aging Analytics Agency, the Longevity Finance Analytics Dashboard is a licensed white-label solution designed for financial corporations (e.g. banks, pension funds, asset management firms and insurance companies) looking to adjust their business models to Longevity-focused banking and **tap into the multi-trillion-dollar market of 1 billion people** in retirement.

The project aims to provide **tangible, data-driven, fast, comprehensive and inexpensive SWOT analysis, customised practical recommendations, benchmarking, forecasting and guidance** needed to transform financial institutions for Longevity-related challenges in the future.



The analytics provided herein can help deliver value to financial institutions and adjust their business models to Longevity-related challenges in the future

Financial Institutions (e.g. Banks, Pension Funds, Asset Management Firms and Insurance Companies)

- SWOT analysis of the most promising entities and technologies
- Real-time monitoring of the developments in the Longevity financial industry
- Benchmarking the most market-ready Longevity finance technologies
- Due diligence of emerging technologies' strengths
- Opportunities forecasting

LONGEVITY INVESTMENT BIG DATA ANALYTICS DASHBOARD

The Longevity Investment Analytics Dashboard developed by InvestTech Advanced Solutions based on the data provided by the Aging Analytics Agency which is active in the industry since 2013 aims to produce **knowledge-based validated investment insights** covering four major Longevity branches: financial Longevity industry, Longevity R&D, Longevity medicine and Longevity technology.

The project generates **quantifiable and advanced data-driven investment recommendations** to conduct **an effective and inexpensive SWOT analysis and due diligence** for Longevity companies and investors, and **real-time financial analytics and consulting** for private and publicly traded companies across 20 Longevity sectors.



The analytics can deliver funding targets to investors, funding to companies and detailed SWOT analysis

Investors

- Comprehensive market analysis
- Due diligence and SWOT analysis of investment targets
- Analysis of the strategies of leading industry investors


Companies

- SWOT analysis of competitors
- Automated business development recommendations
- AI-based matching with investors

LONGEVITY GOVERNANCE BIG DATA ANALYTICS DASHBOARD

The Longevity Governance Dashboard brings access to continuous monitoring of the specific governmental policy activities directly impacting both National Healthy Longevity and Longevity Industrialisation, and to consistently **tracking and analysis of data points related to government-led Longevity Development initiatives.**

Its aim is to deliver strategic decision-makers across the private sector, global investment community, financial industry, and governance **access to Big Data analytics and visualisation, market intelligence, competitive analysis, technology and company benchmarking, SWOT analysis, practical recommendations** and other strategic toolset capable of handling the unprecedented complexity and multidimensionality of the full-scope Global Longevity public and private sector ecosystem.



The analytics provided herein identifies factors with the greatest effect on the gap between life expectancy and Health-Adjusted Life Expectancy

Government Agencies, Healthcare, Economy & Industrial Development Ministries and International Policy Organisations

- Features region-specific recommendation packs
- Provides tangible and practical recommendations tuned to the specifics of individual countries
- Precision Health

Longevity Industry Investment

Overview by Region




InvestTech
Advanced
Solutions



Geographic Distribution of Investors in 2025

The United States remains firmly in the lead by the number of Longevity-focused companies (50%). Asia secures the third spot, representing 12% of the global market in 2024.

The United Kingdom contributes 8%, while China holds a 4% share. Canada and Australia follow with 2% each. Steady growth in the Longevity industry is anticipated in Europe, driven by an increasing number of public offerings.




Geographic Distribution of Investors in 2025

The first chart represents the top 10 countries with the most investments in the Longevity Industry (as of 2024). The second chart shows the top 10 countries by the number of Longevity-focused companies (as of 2024). The USA is the clear leader here, with approximately 43,000 companies operating in this sector.


The United Kingdom follows with 6,600 companies, while Canada ranks third with 2,500 companies. China holds the fourth position with 3,500 companies, closely followed by Germany (3,600) and Japan (3,300).

France and India each contribute around 2,500 companies. Saudi Arabia and Spain complete the top 10 with 850 and 840 companies, respectively.

Total Investment by Countries




Number of Companies



Geographic Distribution of Investors in 2025

This chart represents the top 5 countries where Longevity Industry companies have received the biggest total investments as of Q1 2024. The USA, being the leader by size of total investments, showed the highest growth rate, (20%) which may indicate rising market among US-based companies, however, compared to 2022 the growth rate would be still negative. China, on the other hand, as the second biggest country by total investments, has shown a third compound growth rate of 15%, while the UK showed 18%; Canada experienced the smallest growth among this top 5 countries, having less than 10% increase, while Germany showed 13%.

Compound Annual Growth Rate of Investments in the Top 5 Longevity Countries by Investment Size in 2023-2024



Longevity Industry Investment

Overview by Subsectors



InvestTech
Advanced
Solutions




Longevity Industry Investment Overview by Subsectors

PharmTech is the largest sector in the Longevity Industry by the amount of funds raised and **P6 Medicine** – by the number of companies involved.


The distribution of investments across different sectors of the Longevity Industry demonstrates that investors tend to invest more in devices (**AgeTech**) than in drug and gene therapies.

Furthermore, as society's focus is shifting towards keeping older people healthy and active for longer, tech-enabled care and mobility aids, as the two key areas of AgeTech, are very likely to attract even higher levels of investment in the near future.

Total Investments Raised by Private Longevity Companies (2024)



Longevity Industry Investment Overview by Subsectors




PharmTech and **P6 Medicine** are the Longevity Industry subsectors that receive the highest volume of investments and have the largest number of companies. The following pages outline the key trends in private investing for the top 5 Longevity Industry subsectors.

Key Market Drivers of PharmTech:

- **PharmTech is becoming a lucrative area for specialised BioTech investors and investment funds (VCs)** just entering the pharma space to include high-risk/high-return companies in their investment portfolios.
- The rise of PharmTech catalyses the **technological expansion of other vendors and service providers**, for example, big data providers, quantum computing providers, and cloud and data storage providers.
- **Tech companies are expanding into the pharma space** by offering specialised services and tools to pharma counterparties and investing directly in disruptive start-ups.
- Today, **advanced technologies (AI, ML, Big Data)** allow companies to offer services for drug development with a higher success rate. In most areas, these solutions provide a unique opportunity to find novel treatments more quickly and at a lower cost.

Longevity Industry Investment Overview by Subsectors



Longevity Industry Investment Overview by Subsectors

Key Market Drivers of PharmTech:

- **PharmTech is becoming a lucrative area for specialised BioTech investors and investment funds (VCs)** just entering the pharma space to include high-risk/high-return companies in their investment portfolios.
- The rise of PharmTech catalyses the **technological expansion of other vendors and service providers**, for example, big data providers, quantum computing providers, and cloud and data storage providers.
- **Tech companies are expanding into the pharma space** by offering specialised services and tools to pharma counterparties and investing directly in disruptive start-ups.
- Today, **advanced technologies (AI, ML, Big Data)** allow companies to offer services for drug development with a higher success rate. In most areas, these solutions provide a unique opportunity to find novel treatments more quickly and at a lower cost.

Top Companies in PharmTech by Investments Activity



Top 10 Countries by Investments Raised in PharmTech



Longevity Industry Investment Overview by Subsectors


Key Market Drivers of Longevity Medicine:

- We are already seeing **a big shift in diagnostics from symptoms analysis to precision analysis** of]molecular predictors, and markers of diseases are predicted to result in far greater cost-effectiveness.
- The discovery and supply of biomedical innovations are being accelerated both by their **increasing implementation in practical medicine** and by **rising demand from informed consumers**.
- **Consumers prefer the P4 model of healthcare**, which is science-based and aims to actively prevent diseases and ageing and enhance wellness without the regular need to visit clinics. The at-home method of testing, monitoring, prevention, and treatment is in keeping with general current lifestyle trends in the modern world.
- **A new Wellness and Longevity Industry has emerged and is expected to supersede the current healthcare industry** in a number of products, becoming a major source of economic growth in the near future.

Top Companies in Longevity Medicine by Investment Activity



Top 10 Countries by Investments in Longevity Medicine




Longevity Industry Investment Overview by Subsectors

Key Market Drivers of Deep Diagnostics:

- It is becoming increasingly clear that there is a demand for preventive diagnostics services among seniors as this population group is intending to remain independent, vital, and healthy for longer periods.
- In the near future, there will be an increasing demand for more accessible and on-hand diagnostics tools. The possible prospective areas of Longevity deep diagnostics may include blood pressure, cancer screening, eye protection solutions, hearing tests, and cholesterol screening.
- As older adults begin experiencing age-related decline and requiring more assistance with daily tasks, they and their family members increasingly wish to receive precise and necessary tests and doctor's appointments. New companies will emerge to respond to these needs with new solutions.

Top Companies in Deep Diagnostics by Investments Activity



Top 10 Countries by Investments in Deep Diagnostics




Longevity Industry Investment Overview by Subsectors


Key Market Drivers of AI for Longevity:

- **The primary goals of AI application in Longevity Industry for the next 5-10 years** will lie in the aggregation, development, and deployment of biomarkers of ageing, health, and Longevity; Preventive Medicine diagnostics and prognostics; Precision Health technologies and therapeutics; and integrated Wealthspan-extending AgeTech and WealthTech solutions for financial wellness across extended periods of Healthy Longevity.
- As **the complexities of Longevity science and technology increase**, and as the volume of data continues to amass, the role of AI in both analysis and comprehension becomes absolutely necessary for continued progress and industry development.
- **Companies advancing AI in Longevity are widely attracting the interest of investment funds across the global market.** The next 5 years may bring new Longevity-focused funds with the more precise expertise necessary to make intelligent investments in such a complex and multidisciplinary industry.

Top Companies in AI in Longevity by Investments Activity



Top 10 Countries by Investments in AI in Longevity



Longevity Industry Investment Overview by Subsectors


Key Market Drivers of Telemedicine:

- **The COVID-19 pandemic has shone a spotlight on the new potential of TeleHealth for complementing in-person care** – especially for people who may face mobility issues in going to a brick-and-mortar office.
- **Telemedicine has proven effective for urgent and one-time visits.** For example, seniors with respiratory infections may use telemedicine solutions to save time and money while still enjoying high-quality healthcare services.
- **Physicians can spot early warning signs associated with worsening chronic conditions** and the onset of new ones, allowing for early intervention and reducing the chances of hospital admission and readmission.
- **More and more companies are emerging with the goal of reducing the cost of healthcare services.** For example, the cost of implementing telemedicine programs in nursing homes could be offset by a reduction in the costs related to transferring residents to and from emergency rooms and physicians' offices.

Top Companies in Telemedicine by Investments Activity



Top 10 Countries by Investments




Longevity Industry Investment

Leading Investors



Leading Investors in Longevity


We can observe 8,744 investors in the Longevity Industry. They are mostly concentrated in North America, where the USA accounts for 92% of North American investors and North America accounts for 48% of all investors globally. The next five countries by number of investors are China, the UK, Canada, Japan, and India.



Leading Investors in Longevity

Venture capital funds are a clear leader among investor types, constituting 32% of the total number of investors. However, we can also see significant interest in the industry among individual and angel investors. Unfortunately, the industry still lacks interest from incubators and accelerator investors, which could provide a huge kick to the industry by providing not only funds but a certain amount of guidance and knowledge as well. Nevertheless, there are already a few accelerators that are significant players such as Y Combinator, 500 Startups, Techstars, etc.


Distribution of Investors by Type in the Longevity Industry in 2025



Leading Investors in Longevity

The above graph shows the strong prevalence of small and medium-sized investors by the number of portfolio companies. Only just over 5% of all investors have more than 82 portfolio companies, with some of these having up to 3,000 companies. Y Combinator is one example of such an investor.

Distribution of Investors by Portfolio Size



Leading Investors in Longevity

Profiling of Top Investors

There are several thousand investment funds that can be classed as investors in the Longevity Industry space. Among them, we have selected investment funds that are focused predominantly on Longevity companies. Those funds are shown below in the table.

Among 500 Longevity-focused public companies, **Healthcare Innovations, Longevity Finance and Wellness and Lifestyle** are the most represented sectors by a number of companies. As society's focus is shifting towards keeping older people healthy and active for longer, life sciences and tech-enabled solutions are key areas that are likely to attract even more investments in the near future.

Investment Fund Name	Category/Focus Area	Key Partners	Region
The Longevity Fund	Early-stage Longevity Startups	Formic Ventures	Global
Longevity Vision Fund	Aging Tech & Biotech	Formic Ventures	Global
Ziegler Link-Age Funds	Healthcare & Longevity Investments	Formic Ventures	USA
SP8CEVC	Venture Capital	Formic Ventures	Europe
Age 1	Longevity Accelerator	Techstars Future of Longevity	Global
Pura Vida Investments	Biotech & Pharma	Techstars Future of Longevity	USA
Emerging Longevity Ventures	Aging Biotech Startups	Techstars Future of Longevity	Europe
F-Prime Capital	Biotech & Health Innovation	Techstars Future of Longevity	Global
Mediterranean Towers Ventures	Senior Care & Aging Services	Third Act Ventures	Middle East
Juvenescence	Biotech & Aging Solutions	Third Act Ventures	Global
Apollo Ventures	Longevity & Healthspan	Third Act Ventures	Europe
Methuselah Fund	Aging Research & Advocacy	Third Act Ventures	USA
Thynk Capital	Health-Tech & Aging Innovations	Independent	Global
Longevitytech.fund	Aging Biotech Solutions	Independent	Europe
Generator Ventures	Tech-Driven Aging Solutions	Independent	USA

Longevity Industry Investment

Leading Investments



InvestTech
Advanced
Solutions




Leading Investments


Most Common Investment Targets

Through analysing the portfolios of the top investors, we have attained the following results. Longevity-focused companies account for 46.2% of the total number of companies that have received funding from top investment funds. Some 35.5% of these companies work in HealthTech, while 14.5% work in PharmTech, and 3.8% provide FinTech products or services.

Distribution of Target Longevity-Focused Companies by Sector



Average Company Age During Investment by Sector




Leading Investments

The regional distribution of the competing investment funds is roughly as one would expect, with the USA taking the lead. This is for the following reasons:

- Most of the HealthTech and healthcare start-ups either were launched in the USA or are aiming to enter the US market.
- The USA has the most highly developed investment market and tools.
- Although the USA's competitors keep attracting significant amounts of diversified cash flow, they are far from reaching the necessary turning point for success.

Regional Distribution of Competing Funds




Leading Investments

The regional distribution among investment targets of competing funds is consistent with the overall distribution of Longevity-related companies.

Interestingly, although many Big Pharma companies are located in the EU, the total number of investment targets in this region is quite small.

This is due to the novelty of the Longevity Industry, with the United States leading globally by the number of HealthTech and healthcare start-ups. Because of legal obstacles in the region, the number of Asia-based investment targets is quite small.


Longevity Industry Portfolio Funding



The infographic outlines the companies that have made significant advancements in tackling the complexity of the Longevity Industry. The key factors taken into account while the assessment are as follows:

- Technological assessment, comparing to existing approaches of other companies active in the specific Longevity Industry subsector;
- Entering into partnerships with market participants and trusted R&D organisations ensuring the enhancement of companies' core products;
- Fundraising dynamics from leading investors;
- The presence of validated products that fit the needs of customers.

Prominent Longevity Companies



Longevity Industry Investment


Dashboard



InvestTech
Advanced
Solutions



Distribution of Public Companies by Longevity Industry Sectors



Among 500 Longevity-focused public companies, **Healthcare Innovations, Longevity Finance and Wellness and Lifestyle** are the most represented sectors by a number of companies. As society's focus is shifting towards keeping older people healthy and active for longer, life sciences and tech-enabled solutions are key areas that are likely to attract even more investments in the near future.

IPOs in 2025

Company Name	Website	Location	Revenue	Product/Focus	IPO Money Raised	Ticker	IPO Date	Longevity Sub Sector
 CG Oncology	cgoncology.com	Irvine, California, USA	Not disclosed	Oncolytic immunotherapies	\$380 million	CGON	25/01/24	Preclinical Studies
 ArriVent Biopharma	arrivent.com	Philadelphia, Pennsylvania, USA	Not disclosed	Targeted cancer therapies	Not disclosed	ARVT	26/01/24	Preclinical Studies
 HaemaLogiX	haemalogix.com	Sydney, New South Wales, Australia	Not disclosed	Treatments for multiple myeloma	\$50 million	HLGX	01/04/24	Preclinical Studies
 Bicar Therapeutics	bicaratx.com	Cambridge, Massachusetts, USA	Not disclosed	Bifunctional antibodies for cancer	Not disclosed	BICR	15/09/24	Preclinical Studies
 MBX Biosciences	mbxbio.com	Carmel, Indiana, USA	Not disclosed	Endocrine disorders therapies	Not disclosed	MBXB	15/09/24	Preclinical Studies
 Zenas BioPharma	zenasbio.com	Waltham, Massachusetts, USA	Not disclosed	Autoimmune disease treatments	Not disclosed	ZENA	15/09/24	Preclinical Studies
 Upstream Bio	upstreambio.com	Cambridge, Massachusetts, USA	Not disclosed	Therapies for inflammatory diseases	\$255 million	UPST	11/10/24	Preclinical Studies
 CAMP4 Therapeutics	camp4tx.com	Cambridge, Massachusetts, USA	Not disclosed	Gene regulation therapies	\$75 million	CAMP	10/10/24	Preclinical Studies
 CAMP4 Therapeutics	odyssseytx.com	Boston, Massachusetts, USA	Not disclosed	Inflammatory diseases and cancer treatments	Not disclosed	ODYS	01/12/24	Preclinical Studies
 Aktis Oncology	aktisoncology.com	Cambridge, Massachusetts, USA	Not disclosed	Radiopharmaceuticals for cancer	Not disclosed	AKTS	01/12/24	Preclinical Studies

Top 20 Publicly Traded Longevity-Focused Companies

NASDAQ



US-Based



UnitedHealth Group
(UNH)
Market Cap: \$500B



Amgen Inc. (AMGN)
Market Cap: \$150B



Gilead Sciences, Inc.
(GILD)
Market Cap: \$100B



Regeneron
Pharmaceuticals, Inc.
(REGN)
Market Cap: \$85B



Vertex
Pharmaceuticals
Incorporated (VRTX)
Market Cap: \$90B



Biogen Inc. (BIIB)
Market Cap: \$50B



Moderna, Inc. (MRNA)
Market Cap: \$60B



China-Based



BeiGene (BGNE)
Market Cap: \$20B



UK-Based



Abcam (ABCM)
Market Cap: \$4B



AstraZeneca PLC (AZN)
Market Cap: \$200B

Euronext Brussel (BR)



Switzerland-Based



Novartis AG (NVS)
Market Cap: \$200B



Sanofi (SNY)
Market Cap: \$120B



Sweden-Based



Getinge (GETI-B)
Market Cap: \$10B

Hong Kong (HKD)



Hong Kong-Based



CRISPR Therapeutics AG
(CRSP)
Market Cap: \$7B



Deep Longevity
Acquired by \$4M

NYSE



US-Based



Pfizer Inc. (PFE)
Market Cap: \$220B



Eli Lilly and Company
(LLY)
Market Cap: \$400B

Other



US-Based



Alnylam
Pharmaceuticals, Inc.
(ALNY)
Market Cap: \$30B



Editas Medicine, Inc.
(EDIT)
Market Cap: \$5B



Sweden-Based




Roche Holding AG
(RHHBY)
Market Cap: \$300B

Longevity Industry Investment

Longevity Investment Analytics Dashboard



Longevity Investment Analytics Dashboard



 182,400
Companies

 102,000
Investors

 6,400
Longevity Organizations

 35,700
Leaders

Dashboards

Longevity International ...

Longevity Club Analysis

Longevity Investment

Longevity Financial Das...

Data

Companies

Investors

Hubs

Longevity Organizations

Clinical Trials

Funding Rounds

Impact Investors

Venture Funds

Books

LONGEVITY INDUSTRY ...

BIOMARKERS OF HUMA...

LONGEVITY FINANCIAL I...

Data Room

Downloadable

Macroparameters




Industry SWOT Analysis




Analytical Reports Library



Longevity Industry Landscape



Network Diagrams



General AI Pharma Market Analysis



 500
Hubs

 4,775,000
Data Points

 9
Super Industries

 48
Industries

CCQQ Assessment T... [Pro](#)

Automated SWOT A... [Pro](#)

Operational Environ... [Pro](#)

Comperative Analys... [Pro](#)

Industry Heatmap C... [Pro](#)

Automated Benchm... [Pro](#)

Automated Chart B... [Pro](#)

Cluster Analysis Tool [Pro](#)

Competitor Analysis... [Pro](#)

Topic Oriented Sub ... [Pro](#)

Automared Industry... [Pro](#)

DataRoom Navigati... [Pro](#)

Interactive Entities ... [Pro](#)

Interactive Leads Da... [Pro](#)

Individual Leads Pro... [Pro](#)

Individual Entities P... [Pro](#)

Evolution Tree Cons... [Pro](#)

Events Monitroing T... [Pro](#)

Indices Builder and ... [Pro](#)

Industry Universe A... [Pro](#)

Interactive Framew... [Pro](#)

Investor Relations A... [Pro](#)

market Prediction a... [Pro](#)

182,400
Companies102,000
Investors6,400
Longevity Organizations35,700
Leaders

Macro Parameters

Month to Date (Apr 1 - 2)

Number of Companies by
Country


Dimension	Number of Companies by Country	vs prev
USA	84,097	
Other	21,406	
UK	14,397	
India	6,948	
Switzerland	5,509	
Canada	5,379	
Germany	4,735	
Japan	4,044	



Longevity International Companies

All Time (Mar 24, 2015 - Jul 9, 2027)

Number of Companies by Super Industry



Last 30 days (Mar 3 - Apr 1)

Number of Companies by Industry

No data to display

500
Hubs4,775,000
Data Points9
Super Industries48
Industries



Longevity Industry Investment Analysis



182,400
Companies



102,000
Investors



6,400
Longevity Organizations



35,700
Leaders

Longevity Investment Digest Q1 2022



INVESTMENT DIGEST

Longevity Industry Q1 2022

www.invest-solutions.tech

www.aginganalytics.com

AI in Pharma Investment Digest, Q3 2021



INVESTMENT DIGEST

AI in PHARMA Q3 2021

www.deep-pharma.tech

www.invest-solutions.tech

AI in Pharma Investment Digest, Q4 2021



INVESTMENT DIGEST

AI in PHARMA Q4 2021

www.deep-pharma.tech

www.invest-solutions.tech

Longevity Financial Institutions, Q3 2021



INVESTMENT DIGEST

Longevity Financial Institutions Q3 2021

www.invest-solutions.tech

www.aginganalytics.com

Longevity Investment Digest, Q3 2021



INVESTMENT DIGEST

Longevity Industry Q3 2021

www.invest-solutions.tech

www.aginganalytics.com

NeuroTech Industry Overview, Q4 2021



INVESTMENT DIGEST

NeuroTech Industry Overview Q4-2021

www.invest-solutions.tech

www.neurotech.com



500
Hubs



4,775,000
Data Points



9
Super Industries



48
Industries



analytics@longevity.group

info@invest-solutions.tech

www.longevity.group/analytics

www.invest-solutions.tech

Aging Analytics Agency (AAA) & InvestTech Advanced Solutions (ITAS) Disclaimer

The information and opinions in this report were prepared by Aging Analytics Agency and InvestTech Advanced Solutions. The information herein is believed by AAA and ITAS to be reliable but AAA and ITAS make no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. AAA and ITAS may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of AAA and ITAS may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of AAA and ITAS and are subject to change without notice. AAA and ITAS have no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.